---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-293003"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:19:34.544700+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Arcellx presents CART-ddBCMA Phase 1 expansion data at ASH; no specific results disclosed in 8-K

## Summary
- Event at 65th ASH Annual Meeting on Dec 11, 2023 in San Diego highlighting CART-ddBCMA Phase 1 expansion trial.
- Trial enrolled patients with relapsed/refractory multiple myeloma.
- Filing does not include numerical efficacy or safety data from the presentation.
- Corporate slides attached as Exhibit 99.1 but full data not reproduced in this filing.

## SEC filing metadata
- accession: 0001193125-23-293003
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312523293003/0001193125-23-293003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312523293003/d659269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-293003
- JSON: https://secwatch.observer/filing/0001193125-23-293003.json
- Plain text: https://secwatch.observer/filing/0001193125-23-293003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.